Currently, pharmacological therapies for T2DM focus on improving insulin sensitivity, delaying carbohydrate absorption in the gastrointestinal tract, stimulating insulin secretion, or increasing glucose excretion via sodium-glucose cotransporter-2 (SGLT2) inhibitors [5]. This evidence concerns the gene INS and type 2 diabetes mellitus.